Myeloid leukemic progenitor cells can be specifically targeted by minor histocompatibility antigen LRH-1-reactive cytotoxic T cells

Blood

Volumn 113, Issue 10, 2009, Pages 2312-2323

  Norde, Wieger J ^a   Overes, Ingrid M ^a   Maas, Frans ^a   Fredrix, Hanny ^a   Vos, Johanna C M ^a   Kester, Michel G D ^b   Van Voort, Robbert Der ^a   Jedema, Inge ^b   Falkenburg, J H Frederik ^b   Schattenberg, Anton V ^a   De Witte, Theo M ^a   Dolstra, Harry ^a,c  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; GAMMA INTERFERON; HLA B7 ANTIGEN; IDARUBICIN; IMATINIB; LIVER RECEPTOR HOMOLOG 1; MINOR HISTOCOMPATIBILITY ANTIGEN; PURINERGIC P2X5 RECEPTOR; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ADD ON THERAPY; ADULT; APOPTOSIS; ARTICLE; BONE MARROW TRANSPLANTATION; CD8+ T LYMPHOCYTE; CELL ISOLATION; CELL MATURATION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DONOR LYMPHOCYTE INFUSION; DRUG MEGADOSE; FEMALE; FUNCTIONAL ASSESSMENT; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; STEM CELL;

EID: 63849156664     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-04-153825     Document Type: Article

References (38)

1. Radich JP, Olavarria E, Apperley JF. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia. Hematol Oncol Clin North Am. 2004;18:685-702.
2. Suciu S, Mandelli F, de Witte T, et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood. 2003;102:1232-1240.
3. Goulmy E. Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy. Immunol Rev. 1997;157:125-140.
4. Bleakley M, Riddell SR. Molecules and mechanisms of the graft-versus-leukaemia effect. Nat Rev Cancer. 2004;4:371-380.
5. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyt transfusions in marrow grafted patients. Blood. 1995;86:2041-2050.
6. Copland M, Fraser AR, Harrison SJ, Holyoake TL. Targeting the silent minority: emerging immu notherapeutic strategies for eradication of malignant stem cells in chronic myeloid leukaemia. Cancer Immunol Immunother. 2005;54:297-306.
7. Hope KJ, Jin L, Dick JE. Human acute myeloid leukemia stem cells. Arch Med Res. 2003;34:507-514.
8. de Rijke B, Horssen-Zoetbrood A, Beekman JM, et al. Aframeshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia. J Clin Invest. 2005;115:3506-3516.
9. Overes IM, de Rijke B, Horssen-Zoetbrood A, et al. Expression of P2X5 in lymphoid malignancies results in LRH-1-specific cytotoxic T-cell-medi-ated lysis. Br J Haematol. 2008;141:799-807.
10. Burrows SR, Kienzle N, Winterhalter A, et al. Peptide-MHC class I tetrameric complexes display exquisite ligand specificity. J Immunol. 2000; 165:6229-6234.
11. Overes IM, LevengaTH, Vos JC, et al. Aberrant expression of the hematopoietic-restricted minor histocompatibility antigen LRH-1 on solid tumors results in efficient cytotoxic T cell-mediated lysis. Cancer Immunol Immunother. 2009;58:429-439.
12. de Graaf AO, van Krieken JH, Tonnissen E, et al. Expression of C-IAP1, C-IAP2 and SURVIVIN discriminates different types of lymphoid malig nancies. Br J Haematol. 2005;130:852-859.
13. Jedema I, van der Werff NM, Barge RM, Willemze R, Falkenburg JH. New CFSE-based assay to determine susceptibility to lysis by cyto-toxic Tcells of leukemic precursor cells within a heterogeneous target cell population. Blood. 2004;103:2677-2682.
14. Martin PJ. How much benefit can be expected from matching for minor antigens in allogeneic marrow transplantation? Bone Marrow Transplant. 1997;20:97-100.
15. Appay V, Dunbar PR, Callan M, et al. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med. 2002;8:379-385.
16. Bonnet D, Warren EH, Greenberg PD, Dick JE, Riddell SR. CD8(+) minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. Proc Natl Acad Sci USA. 1999;96:8639-8644.
17. von dem Borne PA, Luxemburg-Heijs SA, Heemskerk MH, et al. Molecular persistence of chronic myeloid leukemia caused by donor T cells specific for lineage-restricted maturation antigens not recognizing immature progenitor-cells. Leukemia. 2006;20:1040-1046.
18. Kloosterboer FM, Luxemburg-Heijs SA, van Soest RA, et al. Direct cloning of leukemia-reactive T cells from patients treated with donor lymphocyte infusion shows a relative dominance of hematopoiesis-restricted minor histocompatibility antigen HA-1 and HA-2 specific Tcells. Leukemia. 2004;18:798-808.
19. Kloosterboer FM, Luxemburg-Heijs SA, van Soest RA, et al. Minor histocompatibility antigenspecific T cells with multiple distinct specificities can be isolated by direct cloning of IFNgamma-secreting T cells from patients with relapsed leukemia responding to donor lymphocyte infusion. Leukemia. 2005;19:83-90.
20. Marijt WA, Heemskerk MH, Kloosterboer FM, et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1-or HA-2-specific T cells caninduce complete remissions of relapsed leukemia. Proc Natl Acad Sci USA. 2003;100:2742-2747.
21. Smit WM, Rijnbeek M, van Bergen CA, et al. T cells recognizing leukemic CD34(+) progenitor cells mediate the antileukemic effect of donor lymphocyte infusions for relapsed chronic myeloid leukemia after allogeneic stem cell transplantation. Proc Natl Acad Sci U S A. 1998;95: 10152-10157.
22. Valitutti S, Muller S, Dessing M, Lanzavecchia A. Different responses are elicited in cytotoxic T lymphocytes by different levels of T cell receptor occupancy. J Exp Med. 1996;183:1917-1921.
23. Faroudi M, Utzny C, Salio M, et al. Lytic versus stimulatory synapse in cytotoxic T lymphocyte/ target cell interaction: manifestation of a dual activation threshold. Proc Natl Acad Sci U S A. 2003; 100:14145-14150.
24. Wiedemann A, Depoil D, Faroudi M, Valitutti S. Cytotoxic T lymphocytes kill multiple targets si-multaneously via spatiotemporal uncoupling of lytic and stimulatory synapses. Proc Natl Acad Sci USA. 2006;103:10985-10990.
25. Ravi R, Fuchs EJ, Jain A, et al. Resistance of cancers to immunologic cytotoxicity and adoptive immunotherapy via X-linked inhibitor of apoptosis protein expression and coexisting defects in mito-chondrial death signaling. Cancer Res. 2006;66: 1730-1739.
26. Dolstra H, Fredrix H, Maas F, et al. Ahuman minor histocompatibility antigen specific for B cell acute lymphoblastic leukemia. J Exp Med. 1999; 189:301-308.
27. den Haan JM, Meadows LM, Wang W, et al. The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. Science. 1998;279:1054-1057.
28. den Haan JM, Sherman NE, Blokland E, et al. Identification of a graft versus host disease-associated human minor histocompatibility antigen. Science. 1995;268:1476-1480.
29. Brickner AG, Evans AM, Mito JK, et al. The PANE1 gene encodes a novel human minor his-tocompatibility antigen that is selectively expressed in B-lymphoid cells and B-CLL. Blood. 2006;107:3779-3786.
30. Slager EH, Honders MW, van der Meijden ED, et al. Identification of the angiogenic endothelial-cell growth factor-1/thymidine phosphorylase as a potential target for immunotherapy of cancer. Blood. 2006;107:4954-4960.
31. Akatsuka Y, Nishida T, Kondo E, et al. Identification of a polymorphic gene, BCL2A1, encoding two novel hematopoietic lineage-specific minor histocompatibility antigens. J Exp Med. 2003;197:1489-1500.
32. Kawase T, Akatsuka Y, Torikai H, et al. Alternative splicing due to an intronic SNP in HMSD generates a novel minor histocompatibility antigen. Blood. 2007;110:1055-1063.
33. Spierings E, Goulmy E. Expanding the immuno-therapeutic potential of minor histocompatibility antigens. J Clin Invest. 2005;115:3397-3400.
34. Marsh SGE, Parham P, Barber LD. The HLA Facts Book. London, United Kingdom: Academic Press.
35. Dermime S, Mavroudis D, Jiang YZ, et al. Immune escape from a graft-versus-leukemia effect may play a role in the relapse of myeloid leuke-mias following allogeneic bone marrow transplantation. Bone Marrow Transplant. 1997;19:989-999.
36. Choi SJ, Lee JH, Lee JH, et al. Treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a high incidence of isolated extramedullary relapse. Leukemia. 2004;18:1789-1797.
37. Imataki O, Ohnishi H, KitanakaA, et al. Isolated extramedullary relapse presenting as autologous lymphocyte response. Am J Hematol. 2008;83: 512-514.
38. Cwynarski K, Laylor R, Macchiarulo E, et al. Ima-tinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia. 2004;18: 1332-1339.